LVTX Lava Tx: Enterprise Value-to-Revenue Multiple

Public company logo of LAVA Therapeutics NV (LVTX)

The secure operations of LAVA Therapeutics N.V. (LVTX) within the EU and US frameworks minimize external threats. The company's price-to-sales multiple demonstrates this stability, with the -781.56 metric serving as the target level. Growth is based on the independence of clinical trials from GDP, although the lack of revenue and risks regarding antibody efficacy exert significant pressure on the capitalization.

Company Value to Revenue: Lava Tx (LVTX) for 11/23/2025 - 12/06/2025

Lava Tx - analytical breakdowns and key metrics (LVTX)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:LAVA Therapeutics NV LVTX
Product sample of LAVA Therapeutics NV

This indicator measures the market value of the business, including net debt, relative to generated sales volume, allowing for an assessment of the premium for future revenue growth. By analyzing the Enterprise Value to revenue ratio for LAVA Therapeutics N.V. (LVTX), an investor can discern the value of immuno-oncology innovations, which remains stable regardless of macroeconomic cycles and inflationary fluctuations, determining the long-term capitalization potential.

Competitor analysis for LAVA Therapeutics N.V.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP